Manufacturer of Controlled Substances; Notice of Application; Lipomed, 47108 [2012-19196]
Download as PDF
<![CDATA[
47108
Federal Register / Vol. 77, No. 152 / Tuesday, August 7, 2012 / Notices
Dated: July 30, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
[FR Doc. 2012–19191 Filed 8–6–12; 8:45 am]
such basic classes of controlled
substances listed in schedules I or II,
BILLING CODE 4410–09–P
which fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C.
DEPARTMENT OF JUSTICE
952(a)(2)(B) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
Drug Enforcement Administration
comments or objections to the issuance
of the proposed registration and may, at
Manufacturer of Controlled
the same time, file a written request for
Substances; Notice of Application;
a hearing on such application pursuant
Lipomed
to 21 CFR 1301.43, and in such form as
Pursuant to Title 21 Code of Federal
prescribed by 21 CFR 1316.47.
Regulations 1301.34 (a), this is notice
Any such written comments or
that on June 13, 2012, Lipomed, One
objections should be addressed, in
Broadway, Cambridge, Massachusetts
quintuplicate, to the Drug Enforcement
02142, made application by letter to the Administration, Office of Diversion
Drug Enforcement Administration
Control, Federal Register Representative
(DEA) for registration as an importer of
(ODL), 8701 Morrissette Drive,
the following basic classes of controlled Springfield, Virginia 22152; and must be
substances:
filed no later than September 6, 2012
This procedure is to be conducted
Drug
Schedule simultaneously with, and independent
of, the procedures described in 21 CFR
Bufotenine (7433) .........................
I
1301.34(b), (c), (d), (e), and (f). As noted
Diethyltryptamine (7434) ..............
I
in a previous notice published in the
1Federal Register on September 23, 1975,
Piperidinocyclohexanecarbonitrile (8603) ...................................
II 40 FR 43745–46, all applicants for
registration to import a basic class of
The company plans to import
any controlled substance in schedules I
analytical reference standards for
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: July 30, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–19196 Filed 8–6–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cerilliant Corporation
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on July 6, 2012, Cerilliant
Corporation, 811 Paloma Drive, Suite A,
Round Rock, Texas 78665–2402, made
application by renewal to the Drug
Enforcement Administration (DEA) for
registration as an importer of the
following basic classes of controlled
substances:
mstockstill on DSK4VPTVN1PROD with NOTICES
Drug
Schedule
Cathinone (1235) .......................................................................................................................................................................................
Methcathinone (1237) ................................................................................................................................................................................
4-Methyl-N-methylcathinone (1248) ..........................................................................................................................................................
N-Ethylamphetamine (1475) ......................................................................................................................................................................
N,N-Dimethylamphetamine (1480) ............................................................................................................................................................
Fenethylline (1503) ....................................................................................................................................................................................
Gamma Hydroxybutyric Acid (2010) .........................................................................................................................................................
JWH–018 (7118) ........................................................................................................................................................................................
JWH–073 (7173) ........................................................................................................................................................................................
JWH–200 (7200) ........................................................................................................................................................................................
Alpha-ethyltryptamine (7249) .....................................................................................................................................................................
Ibogaine (7260) ..........................................................................................................................................................................................
CP–47497 (7297) ......................................................................................................................................................................................
CP–47497 C8 Homologue (7298) .............................................................................................................................................................
Lysergic acid diethylamide (7315) .............................................................................................................................................................
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) .............................................................................................................................
Marihuana (7360) ......................................................................................................................................................................................
Tetrahydrocannabinols (7370) ...................................................................................................................................................................
Mescaline (7381) .......................................................................................................................................................................................
3,4,5-Trimethoxyamphetamine (7390) .......................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (7391) ............................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (7392) ........................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (7395) ............................................................................................................................................
2,5-Dimethoxyamphetamine (7396) ..........................................................................................................................................................
3,4-Methylenedioxyamphetamine (7400) ..................................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (7404) ......................................................................................................................................
3,4-Methylenedioxymethamphetamine (7405) ..........................................................................................................................................
4-Methoxyamphetamine (7411) .................................................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine (7431) ................................................................................................................................................
Alpha-methyltryptamine (7432) ..................................................................................................................................................................
Diethyltryptamine (7434) ............................................................................................................................................................................
Dimethyltryptamine (7435) .........................................................................................................................................................................
Psilocybin (7437) .......................................................................................................................................................................................
Psilocyn (7438) ..........................................................................................................................................................................................
VerDate Mar<15>2010
16:52 Aug 06, 2012
Jkt 226001
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 77, Number 152 (Tuesday, August 7, 2012)]
[Notices]
[Page 47108]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-19196]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Lipomed
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on June 13, 2012, Lipomed, One Broadway, Cambridge,
Massachusetts 02142, made application by letter to the Drug Enforcement
Administration (DEA) for registration as an importer of the following
basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Bufotenine (7433)............................................ I
Diethyltryptamine (7434)..................................... I
1-Piperidinocyclohexanecarbonitrile (8603)................... II
------------------------------------------------------------------------
The company plans to import analytical reference standards for
distribution to its customers for research and analytical purposes.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedules I or II, which fall under the authority
of section 1002(a)(2)(B) of the Act 21 U.S.C. 952(a)(2)(B) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR
1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than September 6, 2012
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substance in
schedules I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: July 30, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-19196 Filed 8-6-12; 8:45 am]
BILLING CODE 4410-09-P
